Incidence of Venous Thromboembolism Based on Caprini Score in Deep Inferior Epigastric Perforator Flap Breast Reconstruction

Abstract Background  Deep inferior epigastric perforator (DIEP) flaps are commonly used for autologous breast reconstruction, but reported rates of venous thromboembolism (VTE) are up to 6.8%. This study aimed to determine the incidence of VTE based on preoperative Caprini score following DIEP breast reconstruction. Methods  This retrospective study included patients who underwent DIEP flaps for breast reconstruction between January 1, 2016 and December 31, 2020 at a tertiary-level, academic institution. Demographics, operative characteristics, and VTE events were recorded. Receiver operating characteristic analysis was performed to determine the area under the curve (AUC) of the Caprini score for VTE. Univariate and multivariate analyses assessed risk factors associated with VTE. Results  This study included 524 patients (mean age 51.2 ± 9.6 years). There were 123 (23.5%) patients with the Caprini score of 0 to 4, 366 (69.8%) with scores 5 to 6, 27 (5.2%) with scores 7 to 8, and 8 (1.5%) patients with scores >8. Postoperative VTE occurred in 11 (2.1%) patients, at a median time of 9 days (range 1–30) after surgery. VTE incidence by the Caprini score was 1.9% for scores 3 to 4, 0.8% for scores 5 to 6, 3.3% for scores 7 to 8, and 13% for scores >8. The Caprini score achieved an AUC of 0.70. A Caprini score >8 was significantly predictive of VTE on multivariable analysis relative to scores 5 to 6 (odds ratio = 43.41, 95% confidence interval = 7.46–252.76, p  < 0.001). Conclusion  In patients undergoing DIEP breast reconstruction, VTE incidence was highest (13%) in Caprini scores greater than eight despite chemoprophylaxis. Future studies are needed to assess the role of extended chemoprophylaxis in patients with high Caprini scores.

[1]  Shoshana W. Ambani,et al.  Standard Fixed Enoxaparin Dosing for Venous Thromboembolism Prophylaxis Leads to Low Peak Anti-Factor Xa Levels in Both Head and Neck and Breast Free Flap Patients. , 2022, Journal of reconstructive microsurgery.

[2]  J. Bernstein,et al.  Prolonged Venous Thromboembolism Prophylaxis May Not Be Necessary for DIEP Flap Breast Reconstruction: A Tertiary Center's 10-Year Experience. , 2022, Journal of reconstructive microsurgery.

[3]  Elizabeth M. Lancaster,et al.  Risk factors for venous thromboembolism after vascular surgery and implications for chemoprophylaxis strategies , 2021, Journal of vascular surgery. Venous and lymphatic disorders.

[4]  C. Pannucci,et al.  Prevention of Venous Thromboembolism in Microvascular Surgery Patients Using Weight-Based Unfractionated Heparin Infusions , 2021, Journal of Reconstructive Microsurgery.

[5]  T. Ballinger,et al.  Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction , 2021, Plastic and reconstructive surgery. Global open.

[6]  M. Crowley,et al.  A novel algorithm to reduce VTE in peri-operative patients on tamoxifen , 2021, Breast.

[7]  J. Hijjawi,et al.  Clinical course of venous thromboembolism following abdominally based microsurgical breast reconstruction: A case series. , 2021, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[8]  A. Chapple,et al.  Hospital Length of Stay Is Associated With Increased Likelihood for Venous Thromboembolism After Total Joint Arthroplasty , 2021, Arthroplasty today.

[9]  C. Pannucci,et al.  Low Anti-Factor Xa Level Predicts 90-Day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis , 2020, Annals of surgery.

[10]  P. Schauer,et al.  Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[11]  C. Pannucci,et al.  Venous Thromboembolism following Microsurgical Breast Reconstruction: A Longitudinal Analysis of 12,778 Patients , 2020, Plastic and reconstructive surgery.

[12]  Scott C. Dolejs,et al.  Perioperative Use of Antiestrogen Therapies in Breast Reconstruction , 2020, Annals of plastic surgery.

[13]  Na Eun Kim,et al.  Standardized Risk Assessment and Risk-Stratified Venous Thromboembolism Prophylaxis for Patients Undergoing Breast Operation. , 2019, Journal of the American College of Surgeons.

[14]  C. Pannucci,et al.  Breast Reconstruction with Free Abdominal Flaps Is Associated with Persistent Lower Extremity Venous Stasis. , 2019, Plastic and reconstructive surgery.

[15]  Dmitry Zavlin,et al.  Management of Microsurgical Patients using Intraoperative Unfractionated Heparin and Thromboelastography , 2018, Journal of Reconstructive Microsurgery.

[16]  Bernard T. Lee,et al.  Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction? , 2018, Plastic and reconstructive surgery.

[17]  C. Pannucci,et al.  Adequacy of Fixed-Dose Heparin Infusions for Venous Thromboembolism Prevention after Microsurgical Procedures , 2018, Journal of Reconstructive Microsurgery.

[18]  A. Modarressi,et al.  Venous thromboembolism events after breast reconstructions with DIEP free flaps in 192 consecutive case. , 2017, Annales de chirurgie plastique et esthetique.

[19]  E. Garfein,et al.  Risk Factors for Postoperative Venous Thromboembolic Complications after Microsurgical Breast Reconstruction , 2017, Journal of Reconstructive Microsurgery.

[20]  R. Bosc,et al.  Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction. , 2017, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[21]  R. Dorfman,et al.  Surgical Duration Impacts Venous Thromboembolism Risk in Microsurgical Breast Reconstruction , 2017, Journal of Reconstructive Microsurgery.

[22]  P. Harris,et al.  Audit of venous thromboembolism in DIEP free flap breast reconstruction. , 2017, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[23]  B. Brooke,et al.  Individualized Venous Thromboembolism Risk Stratification Using the 2005 Caprini Score to Identify the Benefits and Harms of Chemoprophylaxis in Surgical Patients: A Meta-analysis , 2017, Annals of surgery.

[24]  Allen Kachalia,et al.  Implementation of a Comprehensive Post-Discharge Venous Thromboembolism Prophylaxis Program for Abdominal and Pelvic Surgery Patients. , 2016, Journal of the American College of Surgeons.

[25]  G. Evans,et al.  The Effects of Perioperative Tamoxifen Therapy on Microvascular Flap Complications in Transverse Rectus Abdominis Myocutaneous/Deep Inferior Epigastric Perforator Flap Breast Reconstruction , 2016, Annals of plastic surgery.

[26]  Michael G. Tecce,et al.  Increased Lower Extremity Venous Stasis May Contribute to Deep Venous Thrombosis Formation after Microsurgical Breast Reconstruction—An Ultrasonographic Study , 2016, Journal of Reconstructive Microsurgery.

[27]  M. Höistad,et al.  Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. , 2016, Breast.

[28]  S. Ariyan,et al.  Benefits and Risks of Prophylaxis for Deep Venous Thrombosis and Pulmonary Embolus in Plastic Surgery: A Systematic Review and Meta-Analysis of Controlled Trials and Consensus Conference , 2016, Plastic and reconstructive surgery.

[29]  M. Hawn,et al.  Association Between Inpatient Surveillance and Venous Thromboembolism Rates After Hospital Discharge. , 2015, JAMA surgery.

[30]  Suhail K. Kanchwala,et al.  Tamoxifen (Selective Estrogen-Receptor Modulators) and Aromatase Inhibitors as Potential Perioperative Thrombotic Risk Factors in Free Flap Breast Reconstruction , 2015, Plastic and reconstructive surgery.

[31]  D. Mahvi,et al.  Surgical duration and risk of venous thromboembolism. , 2015, JAMA surgery.

[32]  N. Adhikari,et al.  Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review , 2014, Critical Care.

[33]  J. Fischer,et al.  Venous Thromboembolism Risk in Mastectomy and Immediate Breast Reconstruction: Analysis of the 2005 to 2011 American College of Surgeons National Surgical Quality Improvement Program Data Sets , 2014, Plastic and reconstructive surgery.

[34]  G. Evans,et al.  Predictive Risk Factors of Venous Thromboembolism in Autologous Breast Reconstruction Surgery , 2014, Annals of plastic surgery.

[35]  R. Timman,et al.  Pulmonary Embolism after Abdominal Flap Breast Reconstruction: Prediction and Prevention , 2013, Plastic and reconstructive surgery.

[36]  M. Fang,et al.  Assessing bleeding risk in patients taking anticoagulants , 2013, Journal of Thrombosis and Thrombolysis.

[37]  K. Eley,et al.  Functional fibrinogen to platelet ratio using thromboelastography as a predictive parameter for thrombotic complications following free tissue transfer surgery: A preliminary study , 2012, Microsurgery.

[38]  A. Khan,et al.  Breast reconstruction with deep inferior epigastric perforator flaps , 2012, Annals of the Royal College of Surgeons of England.

[39]  D. Smith Venous Thromboembolism following Microsurgical Breast Reconstruction: An Objective Analysis in 225 Consecutive Patients Using Low-Molecular-Weight Heparin Prophylaxis , 2012 .

[40]  J. Rubin,et al.  Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. , 2011, Journal of the American College of Surgeons.

[41]  Bernard T. Lee,et al.  Patient Satisfaction in Postmastectomy Breast Reconstruction: A Comparative Evaluation of DIEP, TRAM, Latissimus Flap, and Implant Techniques , 2010, Plastic and reconstructive surgery.

[42]  C. Pannucci,et al.  Venous Thromboembolic Disease in Autogenous Breast Reconstruction , 2009, Annals of plastic surgery.

[43]  M. Huo,et al.  Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. , 2009, Clinical therapeutics.

[44]  A. Madan,et al.  Anti-Xa Levels in Bariatric Surgery Patients Receiving Prophylactic Enoxaparin , 2008, Obesity surgery.

[45]  C. Kirwan,et al.  Prevention of venous thromboembolism in surgical patients with breast cancer , 2007, The British journal of surgery.

[46]  H. Chew,et al.  Incidence of venous thromboembolism and the impact on survival in breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  F. Parazzini,et al.  A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery: The @RISTOS Project , 2006, Annals of surgery.

[48]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[49]  J. Caprini Thrombosis risk assessment as a guide to quality patient care. , 2005, Disease-a-month : DM.

[50]  P. Blondeel,et al.  Bilateral Autogenous Breast Reconstruction Using Perforator Free Flaps: A Single Center’s Experience , 2004, Plastic and reconstructive surgery.

[51]  R. Allen,et al.  Bilateral Breast Reconstruction with the Deep Inferior Epigastric Perforator (DIEP) Flap: An Experience with 280 Flaps , 2004, Annals of plastic surgery.

[52]  C. Kearon Duration of venous thromboembolism prophylaxis after surgery. , 2003, Chest.

[53]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[54]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[55]  J. Mackay IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-1) - a randomised prevention trial , 2002 .

[56]  F. Alexander,et al.  Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial , 1995, BMJ.